Emmessar Biotech & Nutrition Limited (BOM:524768)
India
· Delayed Price · Currency is INR 25.10
+0.54 (2.20%)
At close: Mar 10, 2026
BOM:524768 Revenue
Emmessar Biotech & Nutrition had revenue of 5.83M INR in the quarter ending December 31, 2025, with 10.08% growth. This brings the company's revenue in the last twelve months to 20.59M, up 4.50% year-over-year. In the fiscal year ending March 31, 2025, Emmessar Biotech & Nutrition had annual revenue of 21.35M with 4.55% growth.
Revenue (ttm)
20.59M
Revenue Growth
+4.50%
P/S Ratio
6.09
Revenue / Employee
1.29M
Employees
16
Market Cap
125.40M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 21.35M | 929.00K | 4.55% |
| Mar 31, 2024 | 20.42M | -4.73M | -18.82% |
| Mar 31, 2023 | 25.15M | 7.42M | 41.83% |
| Mar 31, 2022 | 17.73M | -66.83M | -79.03% |
| Mar 31, 2021 | 84.56M | 37.03M | 77.89% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cian Healthcare | 232.80M |
| Norris Medicines | 94.44M |
| Desh Rakshak Aushdhalaya | 57.72M |
| Ortin Global | 1.12M |
| Colinz Laboratories | 58.40M |
| Beryl Drugs | 176.65M |
| Hamps Bio | 71.20M |
| Zenith Healthcare | 113.86M |